Phase 4
Completed N=11
Using Clonidine to Improve Leg Weakness in People With Heart Failure
Source: ClinicalTrials.gov NCT00858845 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcomePrimary: Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity — -0.3; 0.07 micromole/min/wet weight
Summary
People with heart failure often have weakness in their leg muscles. This study will determine whether the leg weakness is due to very high adrenaline levels and whether the medication clonidine can improve leg weakness.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity |
-0.3; 0.07 | — |
| SECONDARY Change in Proportion of Type 1 Fibers |
-4.6; -5.6 | — |
Eligibility Criteria
Inclusion Criteria
- Heart failure
Exclusion Criteria
- Currently on Coumadin therapy
- Experienced a heart attack in the 3 months before study entry
- Medically unable to receive clonidine
- Advanced kidney or liver disease
Data sourced from ClinicalTrials.gov (NCT00858845). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.